• BioDelivery Sciences International Inc., of Morrisville, N.C., received an initial $2 million payment under a July clinical development and license agreement with CDC IV LLC, an affiliate of Clinical Development Capital LLC. The payment resulted from BioDelivery’s achievement of certain milestones in the development of its BEMA Fentanyl formulation. CDC will provide up to a total of $7 million in funding for Phase III trials relating to BEMA Fentanyl, a narcotic introduced to patients via BioDelivery’s oral BEMA patch.

• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., submitted a new drug application for Bio-E-Gel (transdermal estradiol gel) to treat moderate to severe hot flashes in menopausal women. The NDA includes data from one pivotal Phase III trial and three additional trials required by the FDA.

• Biovitrum AB, of Stockholm, Sweden, acquired the exclusive license and distribution rights to Aloxi (palonosetron hydrochloride) in Nordic territories from Helsinn Healthcare SA, of Lugano, Switzerland. The product, marketed in the U.S. by MGI Pharma Inc., of Minneapolis, is a long-lasting antiemetic belonging to the second generation of serotonin (5-HT3) antagonists, the leading class for the prevention of nausea and vomiting induced by chemotherapy. In the U.S., more than 3 million treatments have been completed. Aloxi is on the market in some European countries, as well as in several countries of Latin America under the trade name Onicit. Helsinn is Aloxi’s worldwide licensor. Financial terms were not disclosed.

• Chemokine Therapeutics Corp., of Vancouver, British Columbia, executed a material transfer agreement with the Dana-Farber Cancer Institute in Boston. The company will supply Dana-Farber with its lead anti-cancer compound, CTCE-9908, a chemokine CXCR4 antagonist, and oncologists will study the benefits of the drug in a series of preclinical studies, investigating its ability to inhibit the growth glioblastoma.

• Diversa Corp., of San Diego, and BASF, of Ludwigshafen, Germany, entered an alliance under which Diversa will be responsible for discovery and optimization of new enzymes, and BASF will handle product and process development, as well as commercialization matters. The agreement is an expansion of the companies’ 2001 collaboration to develop biocatalysts. Financial terms were not disclosed.

• Elusys Therapeutics Inc., of Pine Brook, N.J., reported that preclinical data of its anthrax drug, Anthim, showed that 100 percent of rabbits receiving a lethal challenge of anthrax spores survived after 34 days when receiving a single dose of Anthim, or when receiving Anthim in combination with a five-day course of levofloxacin, compared to 33 percent of the rabbits receiving levofloxacin alone. The data were presented at the American Society of Microbiology Biodefense Research conference in Washington.

• InNexus Biotechnology Inc., of Scottsdale, Ariz., introduced its SuperAntibody Bioequivalent program, following the completion of initial comparative feasibility studies to FDA-cleared antibodies for four SuperAntibody Bioequivalent antibodies. The company also announced that it is relocating its corporate headquarters from Vancouver, British Columbia, to the Mayo Clinic MCCRB Building in Scottsdale.

• Lorus Therapeutics Inc., of Toronto, said it will not proceed with a tax assisted financing as announced on Jan.17, since certain conditions precedent to the closing of the transaction have not been met. The company had said that it signed a term sheet to raise net proceeds of $21.6 million in a tax-assisted financing expected to close Feb. 15. With the transaction, the company intended to license certain patents relating to product candidates, Virulizin, GTI-2040 and GTI-2501 in designated countries as part of a transfer of technology businesses to a limited partnership.

• Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass., entered a six-year, renewable agreement with MDS Nordion Inc., of Ottawa, Ontario, for the commercial manufacture and supply of Zemiva (iodofiltic acid I 123). The molecular imaging pharmaceutical is being developed by Molecular Insight for the diagnosis of cardiac ischemia, and the company’s initial target market is the emergency department setting, in which an estimated 5 million to 8 million patients in the U.S. present each year with chest pain. Further terms were not disclosed.

• Neurochem Inc., of Laval, Quebec, said a subsidiary of Picchio Pharma Inc., of Montreal, exercised a warrant previously issued under a February 2003 private placement and scheduled to expire Feb. 18, 2006, generating proceeds to Neurochem of about C$9.4 million (US$8.1 million), and resulting in the issuance to Picchio of 1.2 million shares. Picchio now owns about 28.6 percent of Neurochem’s outstanding shares.

• ReNeuron Group plc, of Guildford, UK, said initial in vivo testing of its ReN004 candidate stem cell lines showed them to have attributes that might favor the reversal of the neurological deficits seen in Parkinson’s disease. The human cell lines were generated using ReNeuron’s patented c-mycERTAM stem cell expansion technology, and were pre-screened for both genetic stability and their ability to differentiate into tyrosine hydroxylase-expressing neurons. TH is a marker for a dopaminergic stem cell phenotype.

No Comments